Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHA for Lipid Peroxidation in Cystic Fibrosis
NCT02690857Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2010
- Primary completion
- May 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of docosahexaenoic acid in cystic fibrosis (CF) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Change in 8-isoprostane level in urine at Day 14. Started May 2010; status: completed.
02
Drugs
docosahexaenoic acid
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02690857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690857.